RxDoctor Payments Data

David Helton

Optometrist · Atmore, ALNPI 1467473835

Payments from drug & device makers

$796in general payments, 2019–2025

Across 18 payments — averaging $44.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$182
  • Alcon$112
  • Bausch & Lomb Americas Inc.$105
  • AbbVie$78
  • LKC Technologies, Inc.$66
  • Kala Pharmaceuticals, Inc.$63
  • plus $190 from 5 others

What the payments were for

  • Food & beverage$77698%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$796 in reported general payments places this provider in the 45th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$121,715
Medicare patients
587
Services billed
7,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost111$53,556
RestasisCyclosporine51$45,094
RocklatanNetarsudil Mesylat/Latanoprost45$25,819
Travoprost48$8,632
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$8,629
Cyclosporine16$8,325
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat449$7,478
Latanoprost636$7,448
Brimonidine Tartrate118$6,752
CombiganBrimonidine Tartrate/Timolol15$5,129
Prednisolone Acetate96$3,733
Timolol Maleate175$3,155
SimbrinzaBrinzolamide/Brimonidine Tart14$2,914
Fluorometholone14$1,098
Doxycycline Hyclate44$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$78$103,780177 claims
AlconSimbrinza$112$2,91414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 749 optometrist providers in Alabama.

Other optometrist in Atmore

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →